Skip to main content
. Author manuscript; available in PMC: 2010 Oct 20.
Published in final edited form as: HIV Clin Trials. 2010 Jan–Feb;11(1):51–58. doi: 10.1310/hct1101-51

Table 3.

Transition table of PN and SPN

Week 24
Week 0 + Missing
Placebo PN + 18 9 (75.0%) 3 (25.0%) 6
8 2 (28.6%) 5 (71.4%) 1
Missing 2 1 0 1
Total n 28 12 (57.9%) 8 (42.1%) 8

SPN + 9 3 (60.0%) 2 (40.0%) 4
17 2 (14.3%) 12 (85.7%) 3
Missing 2 1 0 1
Total n 28 6 (26.3%) 14 (73.7%) 8

VCV PN + 54 34 (82.9%) 7 (17.1%) 13
33 10 (34.5%) 19 (65.5%) 4
Missing 3 0 0 3
Total n 90 44 (62.9%) 26 (37.1%) 20

SPN + 35 21 (77.8%) 6 (22.2%) 8
53 3 (6.3%) 45 (93.7%) 5
Missing 2 0 0 2
Total n 90 24 (32.0%) 51 (68.0%) 15

Note: PN = peripheral neuropathy; SPN = symptomatic neuropathy; VCV = vicriviroc.